Cargando…
Case Report: Favorable Response and Manageable Toxicity to the Combination of Camrelizumab, Oxaliplatin, and Oral S-1 in a Patient With Advanced Epstein–Barr Virus-Associated Gastric Cancer
Some pertinent studies have demonstrated that Epstein–Barr virus-associated gastric cancer (EBVaGC) patients showed a favorable clinical outcome to immunotherapy and Epstein–Barr virus (EBV)-positive status might be a potential biomarker for immunotherapy in gastric cancer (GC). However, knowledge o...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8791849/ https://www.ncbi.nlm.nih.gov/pubmed/35096571 http://dx.doi.org/10.3389/fonc.2021.759652 |
_version_ | 1784640274247450624 |
---|---|
author | Lv, Wanrui Cheng, Ke Li, Xiaofen Feng, Lusi Li, Hancong Li, Jia Chang, Chen Cao, Dan |
author_facet | Lv, Wanrui Cheng, Ke Li, Xiaofen Feng, Lusi Li, Hancong Li, Jia Chang, Chen Cao, Dan |
author_sort | Lv, Wanrui |
collection | PubMed |
description | Some pertinent studies have demonstrated that Epstein–Barr virus-associated gastric cancer (EBVaGC) patients showed a favorable clinical outcome to immunotherapy and Epstein–Barr virus (EBV)-positive status might be a potential biomarker for immunotherapy in gastric cancer (GC). However, knowledge of given exposure to EBVaGC to the first-line immunotherapy is largely inadequate. Moreover, whether camrelizumab can be as effective as other PD-1 inhibitors in the treatment of advanced EBVaGC has not been reported. We report a case of advanced EBVaGC patient with a positive expression of PD-L1, enriched PD-L1+CD68+macrophages, and high TMB who had a long-term partial response and manageable toxicity to the combined approach of camrelizumab (a novel PD-1 inhibitor) and oxaliplatin plus oral S-1 (SOX). As the first-line treatment of advanced EBVaGC patients, camrelizumab combined with SOX regimen may provide a novel combined approach with favorable response and manageable safety. Combination of multiple biomarkers could have a higher effective predictive capacity to immunotherapy. Integrated treatment (chemo-immunotherapy and radiotherapy) might be the optimal strategy for patients with oligometastasis. It deserves prospective research to further validate the efficacy. |
format | Online Article Text |
id | pubmed-8791849 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-87918492022-01-28 Case Report: Favorable Response and Manageable Toxicity to the Combination of Camrelizumab, Oxaliplatin, and Oral S-1 in a Patient With Advanced Epstein–Barr Virus-Associated Gastric Cancer Lv, Wanrui Cheng, Ke Li, Xiaofen Feng, Lusi Li, Hancong Li, Jia Chang, Chen Cao, Dan Front Oncol Oncology Some pertinent studies have demonstrated that Epstein–Barr virus-associated gastric cancer (EBVaGC) patients showed a favorable clinical outcome to immunotherapy and Epstein–Barr virus (EBV)-positive status might be a potential biomarker for immunotherapy in gastric cancer (GC). However, knowledge of given exposure to EBVaGC to the first-line immunotherapy is largely inadequate. Moreover, whether camrelizumab can be as effective as other PD-1 inhibitors in the treatment of advanced EBVaGC has not been reported. We report a case of advanced EBVaGC patient with a positive expression of PD-L1, enriched PD-L1+CD68+macrophages, and high TMB who had a long-term partial response and manageable toxicity to the combined approach of camrelizumab (a novel PD-1 inhibitor) and oxaliplatin plus oral S-1 (SOX). As the first-line treatment of advanced EBVaGC patients, camrelizumab combined with SOX regimen may provide a novel combined approach with favorable response and manageable safety. Combination of multiple biomarkers could have a higher effective predictive capacity to immunotherapy. Integrated treatment (chemo-immunotherapy and radiotherapy) might be the optimal strategy for patients with oligometastasis. It deserves prospective research to further validate the efficacy. Frontiers Media S.A. 2022-01-13 /pmc/articles/PMC8791849/ /pubmed/35096571 http://dx.doi.org/10.3389/fonc.2021.759652 Text en Copyright © 2022 Lv, Cheng, Li, Feng, Li, Li, Chang and Cao https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Lv, Wanrui Cheng, Ke Li, Xiaofen Feng, Lusi Li, Hancong Li, Jia Chang, Chen Cao, Dan Case Report: Favorable Response and Manageable Toxicity to the Combination of Camrelizumab, Oxaliplatin, and Oral S-1 in a Patient With Advanced Epstein–Barr Virus-Associated Gastric Cancer |
title | Case Report: Favorable Response and Manageable Toxicity to the Combination of Camrelizumab, Oxaliplatin, and Oral S-1 in a Patient With Advanced Epstein–Barr Virus-Associated Gastric Cancer |
title_full | Case Report: Favorable Response and Manageable Toxicity to the Combination of Camrelizumab, Oxaliplatin, and Oral S-1 in a Patient With Advanced Epstein–Barr Virus-Associated Gastric Cancer |
title_fullStr | Case Report: Favorable Response and Manageable Toxicity to the Combination of Camrelizumab, Oxaliplatin, and Oral S-1 in a Patient With Advanced Epstein–Barr Virus-Associated Gastric Cancer |
title_full_unstemmed | Case Report: Favorable Response and Manageable Toxicity to the Combination of Camrelizumab, Oxaliplatin, and Oral S-1 in a Patient With Advanced Epstein–Barr Virus-Associated Gastric Cancer |
title_short | Case Report: Favorable Response and Manageable Toxicity to the Combination of Camrelizumab, Oxaliplatin, and Oral S-1 in a Patient With Advanced Epstein–Barr Virus-Associated Gastric Cancer |
title_sort | case report: favorable response and manageable toxicity to the combination of camrelizumab, oxaliplatin, and oral s-1 in a patient with advanced epstein–barr virus-associated gastric cancer |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8791849/ https://www.ncbi.nlm.nih.gov/pubmed/35096571 http://dx.doi.org/10.3389/fonc.2021.759652 |
work_keys_str_mv | AT lvwanrui casereportfavorableresponseandmanageabletoxicitytothecombinationofcamrelizumaboxaliplatinandorals1inapatientwithadvancedepsteinbarrvirusassociatedgastriccancer AT chengke casereportfavorableresponseandmanageabletoxicitytothecombinationofcamrelizumaboxaliplatinandorals1inapatientwithadvancedepsteinbarrvirusassociatedgastriccancer AT lixiaofen casereportfavorableresponseandmanageabletoxicitytothecombinationofcamrelizumaboxaliplatinandorals1inapatientwithadvancedepsteinbarrvirusassociatedgastriccancer AT fenglusi casereportfavorableresponseandmanageabletoxicitytothecombinationofcamrelizumaboxaliplatinandorals1inapatientwithadvancedepsteinbarrvirusassociatedgastriccancer AT lihancong casereportfavorableresponseandmanageabletoxicitytothecombinationofcamrelizumaboxaliplatinandorals1inapatientwithadvancedepsteinbarrvirusassociatedgastriccancer AT lijia casereportfavorableresponseandmanageabletoxicitytothecombinationofcamrelizumaboxaliplatinandorals1inapatientwithadvancedepsteinbarrvirusassociatedgastriccancer AT changchen casereportfavorableresponseandmanageabletoxicitytothecombinationofcamrelizumaboxaliplatinandorals1inapatientwithadvancedepsteinbarrvirusassociatedgastriccancer AT caodan casereportfavorableresponseandmanageabletoxicitytothecombinationofcamrelizumaboxaliplatinandorals1inapatientwithadvancedepsteinbarrvirusassociatedgastriccancer |